Clinical Trial Update: An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Open-label Phase 1/2 trial evaluating ASP-1929 photoimmunotherapy in combination with anti-PD1 therapy for EGFR-expressing advanced solid tumors; the study incl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Squamous Cell Carcinoma
• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• ASP-1929 Photoimmunotherapy (ASP-1929)
• Anti-PD1 therapy

Snippet

Sponsor: Rakuten Medical, Inc. | Conditions: Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head-and-neck Squamous-cell Carcinoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING